ReviewAnnual review of physiology2014
Glucagon-like peptide-1: glucose homeostasis and beyond.
Review in Annual review of physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06243536 (The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients), which is not on this map. Cited by 76 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients
Who cites it
76 citing papers in PubMed, 3 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.Frontiers in endocrinology · 2022Pooled it
- Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis.Nutrition journal · 2020Pooled it
- Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.Journal of diabetes investigation · 2018Pooled it
- Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.Diabetes & metabolism journal · 2020Trial
- Phytosterols and inulin-enriched soymilk increases glucagon-like peptide-1 secretion in healthy men: double-blind randomized controlled trial, subgroup study.BMC research notes · 2018Trial
- Improving Effect of the Acute Administration of Dietary Fiber-Enriched Cereals on Blood Glucose Levels and Gut Hormone Secretion.Journal of Korean medical science · 2016Trial
- Lactate-activated GPR81/FARP1 signaling drives insulin-independent glucose uptake and metabolic control.Cell research · 2026Article
- Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders.Journal of bone metabolism · 2025Article
- Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential.Toxicology reports · 2025Review
- Obesity: pathophysiology and therapeutic interventions.Molecular biomedicine · 2025Review
- Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity.Integrated pharmacy research & practice · 2025Review
- Pathogenesis of type 2 diabetes in Japan and East Asian populations: Basic and clinical explorations.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2025Review
- Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions - a narrative review.The American journal of clinical nutrition · 2024Review
- Role of Incretins in Muscle Functionality, Metabolism, and Body Composition in Breast Cancer: A Metabolic Approach to Understanding This Pathology.Biomedicines · 2024Article
- Nutrition at the Intersection between Gut Microbiota Eubiosis and Effective Management of Type 2 Diabetes.Nutrients · 2024Review
- Food order affects blood glucose and insulin levels in women with gestational diabetes.Frontiers in nutrition · 2024Article
- Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus.Clinical medicine insights. Endocrinology and diabetes · 2024Review
- Human anaerobic microbiome: a promising and innovative tool in cancer prevention and treatment by targeting pyruvate metabolism.Cancer immunology, immunotherapy : CII · 2023Review
- An overview of fermentation in the food industry - looking back from a new perspective.Bioresources and bioprocessing · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 (GLP-1), an incretin hormone secreted primarily from the intestinal L-cells in response to meals, modulates nutrient homeostasis via actions exerted in multiple tissues and cell types. GLP-1 and its analogs, as well as compounds that inhibit endogenous GLP-1 breakdown, have become an effective therapeutic strategy for many subjects with type 2 diabetes. Here we review the discovery of GLP-1; its synthesis, secretion, and elimination from the circulation; and its multiple pancreatic and extrapancreatic effects. Finally, we review current options for GLP-1-based diabetes therapy, including GLP-1 receptor agonism and inhibition of GLP-1 breakdown, as well as the benefits and drawbacks of different modes of therapy and the potential for new therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.